Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Open accessThe DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.
Abstract
Benzimidazoles have shown significant promise for repurposing as a cancer therapy. The aims of this review are to investigate the possibilities and limitations of the anti-cancer effects of benzimidazole anthelmintics and to suggest ways to overcome these limitations. This review included studies on the anti-cancer effects of 11 benzimidazoles. Largely divided into three parts, i.e., preclinical anti-cancer effects, clinical anti-cancer effects, and pharmacokinetic properties, we examine the characteristics of each benzimidazole and attempt to elucidate its key properties. Although many studies have demonstrated the anti-cancer effects of benzimidazoles, there is limited evidence regarding their effects in clinical settings. This might be because the clinical trials conducted using benzimidazoles failed to restrict their participants with specific criteria including cancer entities, cancer stages, and genetic characteristics of the participants. In addition, these drugs have limitations including low bioavailability, which results in insufficient plasma concentration levels. Additional studies on whole anti-cancer pathways and development strategies, including formulations, could result significant enhancements of the anti-cancer effects of benzimidazoles in clinical situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the doses used in this study were lower than those in the case series by Chiang et al. [1] (1 g/day, three times of week), FBZ still appears to be effective.”
From Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To our knowledge, this is only the second case series documenting such outcomes after Stanford University Medical Center research group led by Chiang et al. [1] provided valuable insights into the potential repurposing of FBZ in cancer treatment.”
From Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, X., Zhao, J., Gao, X., Pei, D., & Gao, C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3992 · Cited by 39
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Jung, K.-W., Won, Y.-J., Kong, H.-J., Lee, E. S., & Registries, T. C. O. P.-B. R. C. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.138 · Cited by 392 · cited 2×
“Mor over, the use of ABZ in combination with ra iation resulted in a sy ergistic increase in the sensitivity of lu g (H153 nd H446) and skin (A375 and A2058) cancer s to radiation [4 ,43].”
BackgroundAlbendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Dayan, A. D. (2003) · Acta Tropica · doi:10.1016/s0001-706x(03)00031-7 · Cited by 371
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review
Iragorri, N., de Oliveira, C., Fitzgerald, N., & Essue, B. (2021) · Current Oncology · doi:10.3390/curroncol28020117 · Cited by 216
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201 · cited 8×
“As drug delivery through the blood-brain barrier (BBB) is cr ti al n the reatment of brain ca cer, the fact that ABZ has been used as a medicine for central nervous system parasitic nfections, because of its physicochemical ability to penetrat th BBB [20], suggests its potential for brain ca cer th rapy.”
BackgroundInfluential(2002) · PubMed · Cited by 170
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.521 · Cited by 165
Spagnuolo, P. A., Hu, J., Hurren, R., Wang, X., Gronda, M., Sukhai, M. A., Di Meo, A., Boss, J., Ashali, I., Beheshti Zavareh, R., et al. (2010) · Blood · doi:10.1182/blood-2009-09-243055 · Cited by 152
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152 · cited 4×
“In addition, OBZ was found to be one of the 10 compounds with tumor-inhibitory effects upon screening 2000 compounds against the M-14 and SK-Mel-19 melanoma cell lines [86].”
BackgroundInfluentialIn vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Pourgholami, M. H., Akhter, J., Wang, L. E., Lu, Y., & Morris, D. L. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0927-6 · Cited by 117
Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30158-6 · Cited by 114
Tang, Y., Liang, J., Wu, A., Chen, Y., Zhao, P., Lin, T., Zhang, M., Xu, Q., Wang, J., & Huang, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05292 · Cited by 104
Noorani, L., Stenzel, M., Liang, R., Pourgholami, M. H., & Morris, D. L. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0082-8 · Cited by 103
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice
Martarelli, D., Pompei, P., Baldi, C., & Mazzoni, G. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0538-0 · Cited by 101
Hossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100 · cited 3×
“In line with the in vitro results, ABZ showed in vivo inhibitory effects in brain [44], breast [19,35], lung [32], and ovarian [41] cancer.”
BackgroundResultBai, R.-Y., Staedtke, V., Rudin, C. M., Bunz, F., & Riggins, G. J. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou234 · Cited by 100
Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
Larsen, A. R., Bai, R.-Y., Chung, J. H., Borodovsky, A., Rudin, C. M., Riggins, G. J., & Bunz, F. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0755-t · Cited by 96
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
Hou, Z.-J., Luo, X., Zhang, W., Peng, F., Cui, B., Wu, S.-J., Zheng, F.-M., Xu, J., Xu, L.-Z., Long, Z.-J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3436 · Cited by 88
Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors
De Witt, M., Gamble, A., Hanson, D., Markowitz, D., Powell, C., Al Dimassi, S., Atlas, M., Boockvar, J., Ruggieri, R., & Symons, M. (2017) · Molecular Medicine · doi:10.2119/molmed.2017.00011 · Cited by 86
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M., Starzetz, T., Harter, P. N., Abhari, B. A., Fulda, S., et al. (2015) · Scientific Reports · doi:10.1038/srep08202 · Cited by 85
Nygren, P., & Larsson, R. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.844359 · Cited by 83
Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition
Oh, E., Kim, Y., An, H., Sung, D., Cho, T., Farrand, L., Jang, S., Seo, J. H., & Kim, J. Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31585 · Cited by 83
Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model
Bai, R.-Y., Staedtke, V., Wanjiku, T., Rudek, M. A., Joshi, A., Gallia, G. L., & Riggins, G. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2681 · Cited by 82
Chu, S. W. L., Badar, S., Morris, D. L., & Pourgholami, M. H. (2009) · PubMed · Cited by 81
Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy
Lin, S., Yang, L., Yao, Y., Xu, L., Xiang, Y., Zhao, H., Wang, L., Zuo, Z., Huang, X., & Zhao, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1303-z · Cited by 77
Zhen, Y., Zhao, R., Wang, M., Jiang, X., Gao, F., Fu, L., Zhang, L., & Zhou, X. (2020) · Theranostics · doi:10.7150/thno.43473 · Cited by 77
Williamson, T., Bai, R.-Y., Staedtke, V., Huso, D., & Riggins, G. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11851 · Cited by 75
Carbendazim Inhibits Cancer Cell Proliferation by Suppressing Microtubule Dynamics
Mythili, Y., Cox, C., Wilson, L., & Jordan, M. A. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143537 · Cited by 74
Harris, P. E., Finlay, I. G., Cook, A., Thomas, K. J., & Hood, K. (2003) · Complementary Therapies in Medicine · doi:10.1016/s0965-2299(03)00126-2 · Cited by 74
Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer
Zhang, L., Bochkur Dratver, M., Yazal, T., Dong, K., Nguyen, A., Yu, G., Dao, A., Bochkur Dratver, M., Duhachek-Muggy, S., Bhat, K., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.08.046 · Cited by 71
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Pourgholami, M. H., Szwajcer, M., Chin, M., Liauw, W., Seef, J., Galettis, P., Morris, D. L., & Links, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1157-8 · Cited by 69
Pilot Study of Albendazole in Patients with Advanced Malignancy
Morris, D. L., Jourdan, J.-L., & Pourgholami, M. H. (2001) · Oncology · doi:10.1159/000055351 · Cited by 66
Albendazole sensitizes cancer cells to ionizing radiation
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-160 · Cited by 66 · cited 4×
“ABZ enhanced ra iation-induced apoptosis by a du l effect of cell ycle arrest in he G2/M phase and i uction of DNA damage, while paclit xel sensitizes m lanoma to radiation only by G2/M cell yc e arr st [42].”
BackgroundInfluentialKrálová, V., Hanušová, V., Staňková, P., Knoppová, K., Čáňová, K., & Skálová, L. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283648c69 · Cited by 66
Zhang, L., Guo, M., Li, J., Zheng, Y., Zhang, S., Xie, T., & Liu, B. (2015) · Molecular BioSystems · doi:10.1039/c5mb00466g · Cited by 65
Zhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., Wei, Q., Fan, J., Song, D., Liao, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14673 · Cited by 65
Albendazole and Praziquantel: Review and Safety Monitoring in Korea
Hong, S.-T. (2018) · Infection & Chemotherapy · doi:10.3947/ic.2018.50.1.1 · Cited by 65 · cited 4×
“FLZ [95] and MBZ [96] have been reported to be mostly excreted in the feces.”
BackgroundInfluentialSimbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y.-S., Fang, H.-B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14990 · Cited by 63
Zhou, F., Du, J. T., & Wang, J. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2927-3 · Cited by 62
Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System
Laudisi, F., Marônek, M., Grazia, A. D., Monteleone, G., & Stolfi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144957 · Cited by 62
Abou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 58
Kim, Y. J., Sung, D., Oh, E., Cho, Y., Cho, T.-M., Farrand, L., Seo, J. H., & Kim, J. Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.020 · Cited by 57
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts
Doudican, N. A., Byron, S. A., Pollock, P. M., & Orlow, S. J. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835a43f1 · Cited by 56
Florio, R., Veschi, S., di Giacomo, V., Pagotto, S., Carradori, S., Verginelli, F., Cirilli, R., Casulli, A., Grassadonia, A., Tinari, N., et al. (2019) · Cancers · doi:10.3390/cancers11122042 · Cited by 54
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53
Younis, N. S., Ghanim, A. M. H., & Saber, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-55666-x · Cited by 53
Hettiarachchi, G., Samanta, S. K., Falcinelli, S., Zhang, B., Moncelet, D., Isaacs, L., & Briken, V. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00723 · Cited by 52
Wang, L.-J., Lee, Y.-C., Huang, C.-H., Shi, Y.-J., Chen, Y.-J., Pei, S.-N., Chou, Y.-W., & Chang, L.-S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.003 · Cited by 50
Shimomura, I., Yokoi, A., Kohama, I., Kumazaki, M., Tada, Y., Tatsumi, K., Ochiya, T., & Yamamoto, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.002 · Cited by 49
Capece, B. P. S., Virkel, G., & Lanusse, C. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2008.11.010 · Cited by 48
Atalay, P., Yeşilay, G., & Tuna, B. G. (2018) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-018-0312-0 · Cited by 48
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas
Kipper, F. C., Silva, A. O., Marc, A. L., Confortin, G., Junqueira, A. V., Neto, E. P., & Lenz, G. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0503-7 · Cited by 47
An, G., Murry, D. J., Gajurel, K., Bach, T., Deye, G. A., Stebounova, L. V., Codd, E. E., Horton, J. D., Gonzalez, A. E., Garcia, H. H., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02255-18 · Cited by 45
Ehteda, A., Galettis, P., Pillai, K., & Morris, D. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-86 · Cited by 44
Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy
Čáňová, K., Rozkydalová, L., & Rudolf, E. (2017) · Acta Medica (Hradec Kralove, Czech Republic) · doi:10.14712/18059694.2017.44 · Cited by 44
Skibinski, C. G., Williamson, T., & Riggins, G. J. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03009-7 · Cited by 44
Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., & Leung, H. Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0681-5 · Cited by 42
Tan, Z., Chen, L., & Zhang, S. (2016) · Scientific Reports · doi:10.1038/srep33534 · Cited by 39
Li, Y., Acharya, G., Elahy, M., Xin, H., & Khachigian, L. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.026 · Cited by 38
Fenbendazole as a potential anticancer drug.
Duan, Q., Liu, Y., & Rockwell, S. (2013) · PubMed · Cited by 37
Ceballos, L., Krolewiecki, A. J., Juaréz, M., Moreno, L., Schaer, F., Álvarez, L., Cimino, R. O., Walson, J. L., & Lanusse, C. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005945 · Cited by 37
Schulz, J. D., Neodo, A., Coulibaly, J. T., & Keiser, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02489-18 · Cited by 37
Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells
Čáňová, K., Rozkydalová, L., Vokurková, D., & Rudolf, E. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.10.025 · Cited by 35
Dogra, N., & Mukhopadhyay, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324228 · Cited by 34
Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis
Jung-Cook, H. H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.72 · Cited by 34
Ehteda, A., Galettis, P., Chu, S. W. L., Pillai, K., & Morris, D. L. (2012) · PubMed · Cited by 33
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
Mrkvová, Z., Uldrijan, S., Pombinho, A., Bartůněk, P., & Slaninová, I. (2019) · Molecules · doi:10.3390/molecules24112152 · Cited by 33
Bach, T., Galbiati, S., Kennedy, J. K., Deye, G. A., Nomicos, E. Y. H., Codd, E. E., Garcia, H. H., Horton, J. D., Gilman, R. H., Gonzalez, A. E., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01018-20 · Cited by 32
In vitro anti‐tubulin effects of mebendazole and fenbendazole on canine glioma cells
Lai, S. R., Castello, S. A., Robinson, A. C., & Koehler, J. W. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12288 · Cited by 31
Kralova, V., Hanušová, V., Caltová, K., Špaček, P., Hochmalová, M., Skálová, L., & Rudolf, E. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.026 · Cited by 30 · cited 2×
“As shown in Figure 1, the effects are mainly mediated through the disruption of microtubule polymerization [21–26], induction of apoptosis [19,26–31], or inhibition of angiogenesis [32,33] and metastasis [19,26,33,34], and as recently reported, autophagy induction [19,56,57,60,102], glycolysis suppression [32,52], imm…”
BackgroundMarkowitz, D., Ha, G., Ruggieri, R., & Symons, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s143096 · Cited by 29
Eguchi, K., Hyodo, I., & Saeki, H. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900039 · Cited by 28
Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia
He, L., Shi, L., Du, Z., Huang, H., Gong, R., Ma, L., Chen, L., Gao, S., Lyu, J., & Gu, H. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.05.006 · Cited by 28
Priotti, J., Baglioni, M. V., García, A., Rico, M. J., Leonardi, D., Lamas, M. C., & Menacho Márquez, M. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1169-y · Cited by 27
Tumor Suppressive Function of NQO1 in Cutaneous Squamous Cell Carcinoma (SCC) Cells
Zhang, Q.-L., Li, X. M., Lian, D., Zhu, M. J., Yim, S., Lee, J., Jiang, R., & Kim, C. D. (2019) · BioMed Research International · doi:10.1155/2019/2076579 · Cited by 27
Sung, S. J., Kim, H. K., Hong, Y.-K., & Joe, Y. A. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.222 · Cited by 26
Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells
Zhang, Q.-L., Lian, D.-D., Zhu, M. J., Li, X. M., Lee, J. K., Yoon, T.-J., Lee, J.-H., Jiang, R.-H., & Kim, C. D. (2019) · BioMed Research International · doi:10.1155/2019/3689517 · Cited by 26
Kawaratani, Y., Matsuoka, T., Hirata, Y., Fukata, N., Nagaoka, Y., & Uesato, S. (2014) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.11.032 · Cited by 24
Hong-lian, L., Sun, H. R., Zhang, B., Liu, S., Deng, S., Weng, Z., Zuo, B., Yang, J., & He, Y. (2019) · Breast Cancer · doi:10.1007/s12282-019-01027-5 · Cited by 23
Activation of aryl hydrocarbon receptor reduces carbendazim-induced cell death
Wei, K., Chen, F.-Y., Lin, C.-Y. G., Gao, G.-L., Kao, W.-Y., Yeh, C.-H., Chen, C.-R., Huang, H.-C., Tsai, W.-R., Jong, K.-J., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.06.004 · Cited by 22
Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01)
Pinto, L. C., Mesquita, F. P., Soares, B. M., da Silva, E. L., Puty, B., de Oliveira, E. H. C., Burbano, R. R., & Montenegro, R. C. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.06.010 · Cited by 22
Wales, C. T. K., Taylor, F. R., Higa, A. T., McAllister, H. A., & Jacobs, A. T. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000231 · Cited by 20
Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-53290-3 · Cited by 20
Belaz, K. R. A., Denadai, M., de Almeida, A. P., Lima, R. T., Vasconcelos, M. H., Pinto, M. M. M., Cass, Q. B., & Oliveira, R. V. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.03.012 · Cited by 19
Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
Rubin, J., Mansoori, S., Blom, K., Berglund, M., Lenhammar, L., Andersson, C., Loskog, A., Fryknäs, M., Nygren, P., & Larsson, R. (2018) · Oncotarget · doi:10.18632/oncotarget.25713 · Cited by 19
Pinto, L. C., Moreira-Nunes, C. A., Soares, B. M., Burbano, R. M. R., de Lemos, J. A. R., & Montenegro, R. C. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.06.007 · Cited by 17
An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole
Rudolf, K., & Rudolf, E. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104930 · Cited by 17
Oxibendazole inhibits prostate cancer cell growth
Chen, Q., Li, Y., Zhou, X., & Li, R. (2017) · Oncology Letters · doi:10.3892/ol.2017.7579 · Cited by 16
Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells
Wang, X., Lou, K., Song, X., Ma, H., Zhou, X., Xu, H., & Wang, W. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115001 · Cited by 16
Choi, E.-K., Kim, S.-W., Nam, E.-J., Paek, J., Yim, G.-W., Kang, M.-H., & Kim, Y.-T. (2011) · Reproductive Sciences · doi:10.1177/1933719111398142 · Cited by 15
Xu, D., Tian, W., Jiang, C., Huang, Z., & Zheng, S. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9897 · Cited by 11
The use of complementary and alternative medicine among cancer patients
Kufel-Grabowska, J., Bartoszkiewicz, M., & Litwiniuk, M. M. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15669 · Cited by 6
Albendazole Sensitizes Melanoma and Small Cell Lung Cancer Cells to Ionizing Radiation
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.06.1248 · Cited by 2
Research works printed but not linked: 1
- Kim E.-Y. Dog Dewormer Goes Out of Stock Amid Rumor of Efficacy for Cancer. Korea Biomedical Review, 27 December 2019 Available online: https://www.koreabiomed.com/news/articleView.html?idxno=7073 (accessed on 1 December 2021)
Cited by
Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review
Marinescu, M. (2023) · Antibiotics · doi:10.3390/antibiotics12071220 · Cited by 127
Recent advances of benzimidazole as anticancer agents
Venugopal, S., Kaur, B., Verma, A., Wadhwa, P. K., Magan, M., Hudda, S., & Kakoty, V. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14236 · Cited by 71
Banerjee, S., Mukherjee, S., Nath, P., Mukherjee, A., Mukherjee, S., Kumar, S. K. A., De, S., & Banerjee, S. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101013 · Cited by 53
Mavvaji, M., & Akkoç, S. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215714 · Cited by 49
Abbade, Y., Kışla, M. M., Hassan, M., Çelik, İ., Doğan, T. S., Mutlu, P., & Ateş‐Alagöz, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c09411 · Cited by 35
Metadata
- Authors
- Song, B., Park, E. Y., Kim, K. J., & Ki, S. H.
- Affiliations
- Chosun University (KR)
- Mokpo National University (KR)
- Corresponding author
- Kim, Kwang Joon
- Ki, Sung Hwan
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-22
- Volume
- 14
- Issue
- 19
- Pages
- 4601
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9559625
- OpenAlex
- W4296992992
- Cited by
- 55
- References
- 104
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 16 · 2023: 12
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Chosun University
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- benzimidazole anthelmintics, drug repurposing, anticancer activity, pharmacokinetics, bioavailability, clinical trials, drug formulation, antiparasitic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.